1.	Doxorubicin Hydrochloride Liposome or Capecitabine as First-Line Chemotherapy in Treating Women With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
2.	Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 26658, NCT00872859
3.	Effects of Granulocyte Colony-Stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: D-0140, NCT00169104
4.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
5.	Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: SWOG-S0226, CAN-NCIC-MAC7, S0226, NCT00075764
6.	Letrozole With or Without Lapatinib in Treating Postmenopausal Women With Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30008, UCLA-0311034-01, NCT00073528
7.	Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP9881B/3001, NCT00081796
8.	A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DOXIL-BCA-3001, NCT00091442
9.	ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104383, NCT00272987
10.	Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-0476, NCT00293540
11.	Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446E2352, NCT00320710
12.	E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-301, NCT00337103
13.	A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR005143, NCT00338286
14.	Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
15.	Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: SWOG-S0500, S0500, CALGB-SWOG-S0500, NCT00382018
16.	Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
17.	A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181094, NCT00373256
18.	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181114, NCT00428220
19.	A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181099, NCT00435409
20.	First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1105, E1105, NCT00520975
21.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
22.	A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR014764, NCT00580112
23.	Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40503, CALGB 40503, NCT00601900
24.	Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/neu-Positive Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA31, MA31, GSK-EGF108919, EUDRACT-2007-004568-27, NCT00667251
25.	Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP12-0606, TRI0-CIRG-012, TRI0-012, NCT00703326